Guided Therapeutics Enters Material Definitive Agreement

TL;DR

Guided Therapeutics just signed a big deal, filing an 8-K on it.

AI Summary

Guided Therapeutics, Inc. announced on December 18, 2024, that it entered into a Material Definitive Agreement. The filing also includes financial statements and exhibits related to this agreement. The company, formerly known as Spectrx Inc., is incorporated in Delaware and headquartered in Peachtree Corners, Georgia.

Why It Matters

This filing indicates a significant new contract or partnership for Guided Therapeutics, which could impact its future revenue and operations.

Risk Assessment

Risk Level: medium — Material definitive agreements can represent significant opportunities or risks depending on the terms, which are not fully detailed in this initial 8-K filing.

Key Players & Entities

• Guided Therapeutics, Inc. (company) — Registrant
• Spectrx Inc. (company) — Former company name
• December 18, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Peachtree Corners, Georgia (location) — Principal executive offices location

FAQ

Key Financial Figures

• $535,000 — f Directors, for the purpose of raising $535,000 in gross proceeds for the Company. Purs
• $0.13 — urchase price per Share and Warrant was $0.13. The Warrants are immediately exercisab
• $0.18 — ance date and have an exercise price of $0.18 per share. The closing of the offering

Filing Documents

• gthp_8k.htm (8-K) — 27KB
• gthp_ex41.htm (EX-4.1) — 72KB
• gthp_ex101.htm (EX-10.1) — 161KB
• 0001477932-24-008254.txt ( ) — 431KB
• gthp-20241218.xsd (EX-101.SCH) — 6KB
• gthp-20241218_lab.xml (EX-101.LAB) — 13KB
• gthp-20241218_cal.xml (EX-101.CAL) — 1KB
• gthp-20241218_pre.xml (EX-101.PRE) — 8KB
• gthp-20241218_def.xml (EX-101.DEF) — 2KB
• gthp_8k_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement . On December 18, 2024, Guided Therapeutics, Inc. (the " Company ") entered into a Securities Purchase Agreement (the " Purchase Agreement ") with certain institutional investors (the " Investors "), including John Imhoff, a member of the Company's Board of Directors, for the purpose of raising $535,000 in gross proceeds for the Company. Pursuant to the terms of the Purchase Agreement, the Company agreed to sell, in a private placement offering, an aggregate of 4,115,386 shares (the " Shares ") of the Company's common stock (" Common Stock ") and warrants (the " Warrants ") to purchase up to 4,115,386 shares of Common Stock (the shares of Common Stock issuable upon exercise of the Warrants, the " Warrant Shares "). The combined purchase price per Share and Warrant was $0.13. The Warrants are immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.18 per share. The closing of the offering pursuant to the Purchase Agreement occurred on December 18, 2024. The Company intends to use the net proceeds from the transactions for general corporate purposes and working capital, including manufacturing expenses for filling product orders placed recently by international distribution partners. The forms of the Purchase Agreement and the Warrant are filed as Exhibits 4.1 and 10.1, respectively, to this Current Report on Form 8-K. The foregoing summaries of the terms of these documents are subject to, and qualified in their entirety by, such documents, which are incorporated herein by reference. 2

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 4.1 Form of Warrant dated December 18, 2024 10.1 Form of Securities Purchase Agreement dated December 18, 2024 104 Cover Page Interactive Date File (embedded within the Inline XBRL document) 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GUIDED THERAPEUTICS, INC. Date: December 20, 2024 /s/ Mark Faupel By: Mark Faupel President and Chief Executive Officer 4

View Full Filing

View this 8-K filing on SEC EDGAR